#USA #Ankeny #Proliant Health #AlbufreeDX #Recombinant Albumin

Proliant Health Unveils AlbufreeDX: A Game-Changer in Recombinant Human Albumin

Proliant Health & Biologicals, a prominent player in the purified protein market, has announced a significant milestone in their product offerings with the launch of AlbufreeDX, a recombinant human albumin (rHA). This new product is poised to meet the rising demand for high-performance, animal-free ingredients particularly important in the fields of diagnostics and life sciences.

For over twenty years, Proliant has established itself as a reliable manufacturer of albumins and other purified proteins, providing exceptional quality and a dependable supply chain across the globe. The company operates out of Ankeny, Iowa, while also having manufacturing capabilities in New Zealand, enabling it to cater to a variety of biotechnology, diagnostics, and healthcare markets seamlessly.

This launch comes at a time when the importance of albumin in assays is taking center stage. Albumin is extensively utilized in diagnostics, biopharmaceutical manufacturing, and research processes due to its unique ability to stabilize proteins, minimize unwanted surface binding, and enhance assay performance. As diagnostic techniques evolve and demand for new analytes and higher sensitivity increases, the need for raw materials that offer unparalleled consistency and purity becomes essential. Traditional albumins derived from animals or humans often bring added complexities, including testing requirements and regulatory hurdles, which AlbufreeDX aims to eliminate.

According to Dr. Christopher Warner, Vice President of Research and Development at Proliant, there is a marked shift among IVD (In Vitro Diagnostics) companies toward incorporating animal- and human-derived materials in their devices to simplify regulatory compliance across various regions. “AlbufreeDX is perfectly aligned with this objective, facilitating easier adherence to global and IVDR compliance, while also supporting our clients' ESG commitments,” he highlighted.

What sets AlbufreeDX apart is its production through precision fermentation, ensuring high purity levels, reliable performance, and excellent lot-to-lot reproducibility. Its versatility makes it suitable for a range of applications, including protein stabilization, surface blocking, reagent formulation, and as a standard reference, especially in scenarios where reducing variability and the risk of animal-derived pathogens is paramount.

“As client expectations evolve, so does our range of products,” remarked Dr. Christopher Detzel, President and CEO of Proliant. He proudly explained that AlbufreeDX is a natural extension of their portfolio that offers a much-needed animal-free albumin alternative while upholding the consistency and scalability that Proliant's customers have come to rely on.

The release of AlbufreeDX not only enhances Proliant's life sciences product collection but also looks forward to future innovations, including AlbufreeTX, aimed at cell culture applications, and AlbufreeCGT to support cell and gene therapy workflows currently emerging in the market.

Proliant’s advancement with AlbufreeDX illustrates their commitment to continually adapting and responding to the needs of the life sciences sector, ultimately rendering their products indispensable tools for laboratories and manufacturers around the world.

For more information, please visit the Proliant Health & Biologicals website, or contact their media representatives at [email protected].